Lilly, Zydus Settle ADHD Generic Infringement Case

Law360, New York (March 9, 2012, 6:29 PM EST) -- Eli Lilly & Co. on Friday ended its New Jersey federal court suit against Zydus Pharmaceuticals USA Inc. as the companies reached an agreement resolving Eli Lilly's claims that the generics maker infringed its patented attention deficit hyperactivity disorder drug.

A consent order filed with the court represented that the pharmaceutical companies had made amends over Zydus' alleged infringement of an Eli Lilly patent through its intention to make a generic copy of Eli Lilly's Strattera ADHD drug.

The patent-in-suit, U.S. Patent Number 5,658,590, titled “Treatment...
To view the full article, register now.